Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 18 of the 19 sources its claims cite were checked for support.

Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review

Open access
Neven, Arjen, Blom, Jan Dirk · 2025 · Harvard Review of Psychiatry

Abstract

Hallucinogen persisting perception disorder (HPPD) is characterized by perceptual phenomena that either linger after substance-use cessation or recur as reperceptions or flashbacks. These symptoms may be either mild and transient or long-lasting and severely burdening. Since evidence for pharmacological treatment of HPPD is unclear, we seek to provide treatment advice based on a systematic review of existing medication studies. Our search yielded 31 studies with 87 participants treated for HPPD with different types of medication. Three observational studies reported substantial symptom reduction for regimens with clonidine, clonazepam, and levetiracetam. The other 28 studies, which consist of case reports and small case series, found largely similar results for benzodiazepines, antiepileptics, antidepressants, and alpha agonists. Of those who received these pharmacological treatments, 28% showed full recovery and 61% partial recovery within a year. When HPPD was triggered by lysergic acid diethylamide, benzodiazepines were ineffective. Notably, several studies described HPPD symptom aggravation upon treatment with the antipsychotic agent risperidone. A list of practice-based treatment methods is provided and suggestions for further research are made.

Overview

CoChat Summary

TL;DR

This systematic review of pharmacological HPPD treatment found no single effective therapy, but benzodiazepines, antiepileptics, antidepressants, and alpha agonists showed favorable effects in mostly small, uncontrolled studies. Across 31 articles and 87 treated individuals, 28% achieved full recovery and 61% partial recovery within a year.

Key findings

  • The search yielded 31 articles describing 87 unique individuals: 51 in observational studies and 36 in case series/case reports. Three observational studies reported substantial symptom reduction with clonidine, clonazepam, and levetiracetam.
  • In the 28 case series/case reports (36 people; 5 female, 14%; mean age 26 years), 10 (28%) showed full recovery, 22 (61%) partial recovery, 2 (6%) no effect, and 2 (6%) symptom aggravation. Full recovery was reported with clonazepam (n=3), valproic acid or lamotrigine (n=2), sertraline or reboxetine (n=2), clonidine (n=1), or risperidone (n=1).
  • Five other papers reported symptom aggravation with risperidone, and when HPPD was triggered by LSD, benzodiazepines were ineffective. Comorbid anxiety or mood disorders were associated with worse outcomes.
  • The authors conclude that no single effective therapeutic can be singled out; further research is needed on the natural course of HPPD and on medication effects in HPPD subtypes.

Methods

  • Systematic search in Medline, Embase, PsycInfo, and Google Scholar for pharmacological HPPD treatments diagnosed by DSM-IV or DSM-5 criteria, including papers published until November 13, 2024; English and Dutch papers were included, with backward searches.
  • Articles were excluded if they contained no original reports on pharmacological HPPD treatment. Data extracted included publication year, participant number, sex, age, illicit substance used, comorbid diagnosis, intervention, results, and follow-up duration.
  • The authors did not consider statistical analysis informative given the relatively small number of publications. The PRISMA-style flow ended with 31 articles for review.

Limitations

  • The paper states there was a lack of randomized, placebo-controlled studies, a relatively small number of evaluated treatment options, breadth of pharmacological agents prescribed, and heterogeneity in design, diagnostic instruments/criteria, study duration, effect evaluation, and follow-up; ranking efficacy was unattainable.
  • The authors note the lack of studies on the natural course of HPPD, no control groups, and that case series/case reports rarely used questionnaires or other assessment tools.
  • They also state possible placebo effect, primary effect on comorbid disorders, underappreciated psychoeducation/psychosocial interventions, underappreciation of natural course, and publication bias; phenomenological overlap with Alice in Wonderland syndrome was rarely assessed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/hrp.0000000000000439

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. PRISMA flow diagram.45
Figure 1. PRISMA flow diagram.45CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

9 Valid · 3 Not valid · 3 Not checked · 34 Own results and interpretations

18 more claims

Create a free account to see all 49 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 47 references

Research works printed but not linked: 5

  1. Hanck, 2013, Persisterende waarnemingsstoornissen na het gebruik van ecstasy., Ned Tijdschr Geneeskd, 157, A5649
  2. Hermle, 2013, Hallucinogen persisting perception disorder (HPPD) and flashback-are they identical?, J Alcohol Drug Dependence, 1, 1
  3. Sullivan, 2013, Case report: hallucinogen persisting perception disorder after exposure to ayahuasca., J Neuropsychiatry Clin Neurosci, 25, 161
  4. Neven, 2014, Synesthesieën in het kader van de persisterende waarnemingsstoornis door hallucinogenen na gebruik van lsd., Tijdschr Psychiatr, 56, 748
  5. Ellis, 1898, Mescal: a new artificial paradise., Contemporary Rev, 73, 130

Cited by

See all 4

Metadata

Authors
Neven, A., & Blom, J. D.
Affiliations
  • Parnassia Groep (NL)
  • Leiden University (NL)
Corresponding author
Blom, Jan Dirk
Venue
Harvard Review of Psychiatry
Published
2025-09
Volume
33
Issue
5
Pages
264-275
ISSN
  • 1067-3229 (ISSN-L)
  • 1465-7309
OpenAlex
W4414162243
Cited by
4
References
47
Citations by year
2026: 3 · 2025: 1
FWCI
0.87
Type
journal article
Language
en
Open access
Locations
  • Harvard Review of Psychiatry (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc-nd)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
  • Leiden Repository (Leiden University) (submittedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
hallucinogen persisting perception disorder, pharmacotherapy, clonidine, clonazepam, levetiracetam, benzodiazepines, antiepileptic drugs, antidepressants, alpha-adrenergic agonists, lysergic acid diethylamide, risperidone, drug-induced hallucinations, symptom recovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review. https://app.cochat.ai/papers/10.1097/hrp.0000000000000439
The paper
Neven, A., & Blom, J. D. (2025). Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review. Harvard Review of Psychiatry. https://doi.org/10.1097/hrp.0000000000000439

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.